In today’s recent session, 1.12 million shares of the Zai Lab Limited ADR (NASDAQ:ZLAB) have been traded, and its beta is 1.08. Most recently the company’s share price was $32.70, and it changed around $3.16 or 10.70% from the last close, which brings the market valuation of the company to $3.59B. ZLAB at last check was trading at a discount to its 52-week high of $39.77, offering almost -21.62% off that amount. The share price’s 52-week low was $13.48, which indicates that the recent value has risen by an impressive 58.78% since then. We note from Zai Lab Limited ADR’s average daily trading volume that its 10-day average is 2.15 million shares, with the 3-month average coming to 1.11 million.
Zai Lab Limited ADR stock received a consensus recommendation rating of Buy, based on a mean score of 1.29. If we narrow it down even further, the data shows that 0 out of 12 analysts rate the stock as a Sell; another 4 rate it as Overweight. Among the rest, 1 recommended ZLAB as a Hold, whereas 7 deemed it a Buy, and 0 rated it as Underweight. Zai Lab Limited ADR is expected to report earnings per share of -0.54 for the current quarter.
Zai Lab Limited ADR (NASDAQ:ZLAB) trade information
Instantly ZLAB has been showing a green trend so far today with a performance of 10.70% on intraday trading today. The performance over the last five days has remained in the green territory. The rise to weekly highs of 33.45 on recent trading dayincreased the stock’s daily price by 2.24%. The company’s shares are currently up 24.86% year-to-date, but still up 13.52% over the last five days. On the other hand, Zai Lab Limited ADR (NASDAQ:ZLAB) is -14.40% down in the 30-day period. We can see from the shorts that 7.32 million shares have been sold at a short interest cover period of 7.5 day(s).
The consensus price target as assigned by Wall Street analysts is $55, which translates to bulls needing to increase their stock price by 40.55% from its current value. Analyst projections state that ZLAB is forecast to be at a low of $55 and a high of $55.
Zai Lab Limited ADR (ZLAB) estimates and forecasts
The year-over-year growth rate is expected to be 41.44%, up from the previous year.
Consensus estimates provided by 4 financial analysts predict the company will bring in an average of 118.39M in revenue for the current quarter. 4 analysts expect Zai Lab Limited ADR to make 130.47M in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 87.15M and 100.5M respectively. Analysts predict that the company’s current quarter sales will jump, forecast at 35.85%. Forecasts for the next quarter put sales growth at 29.81%.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -3.18%.
ZLAB Dividends
Zai Lab Limited ADR’s next quarterly earnings report is expected to be released on 2025-Feb-26.
Zai Lab Limited ADR (NASDAQ:ZLAB)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 1.44% of Zai Lab Limited ADR shares, and 60.61% of them are in the hands of institutional investors. The stock currently has a share float of 61.49%. Zai Lab Limited ADR stock is held by 188.0 institutions, with PRICE T ROWE ASSOCIATES INC /MD/ being the largest institutional investor. By 2024-06-30, it held 1.7037% of the shares, which is about 1.66 million shares worth $28.73 million.
WELLINGTON MANAGEMENT GROUP LLP, with 0.73% or 7.12 million shares worth $123.47 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
New World Fund Inc and VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund were the top two Mutual Funds as of Jan 31, 2025 . The former held 3.28 shares worth $104.85 million, making up 2.99% of all outstanding shares. On the other hand, VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund held roughly 2.9 shares worth around $92.58 million, which represents about 2.64% of the total shares outstanding.
